PhaseV vs QuantHealth (2026)
PhaseV and QuantHealth help sponsors test clinical development choices before committing to a trial. PhaseV emphasizes trial design and treatment response analysis; QuantHealth simulates patient responses and aggregates them into predicted trial results. PhaseV's Trial Optimizer compares fixed, adaptive and Bayesian designs across power, recruitment, duration and cost. Response Optimizer investigates differences between patient groups, with a retrospective Oramed oral insulin analysis informing an amended protocol. Customers can license modules or commission supported analytical projects. Annual Trial Optimizer Exploration Access starts at $50,000, with advanced optimization and additional services carrying separate scope. Retrospective responder findings still await a prospective test of clinical benefit. QuantHealth combines drug biology with a large real world patient database to simulate protocol, indication and enrollment choices. Outputs include virtual readouts, enrollment curves and success estimates for development and portfolio teams. Its reported predictive accuracy and trial examples lack a complete definition of accuracy, denominator and independent validation. Nor are its limits for unfamiliar mechanisms and populations described. PhaseV fits teams comparing statistical designs and exploring which patient groups may respond within a program. QuantHealth fits teams examining predicted therapy response and trial outcomes across development alternatives. Both support decisions made by sponsor teams; simulated results are inputs to planning, not observed outcomes of a future study.
- Fixed, adaptive and Bayesian designs need direct comparison.
- Teams want to investigate treatment effect differences across subgroups.
- Statistical power, recruitment and cost tradeoffs are central.
- An annual software purchase route is useful.
- The task is predicting patient response to an investigational therapy.
- Sponsors want simulated readouts across protocol alternatives.
- Indication and portfolio decisions accompany trial design.
- Enrollment curves and success estimates are desired outputs.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. PhaseV and QuantHealth are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | PhaseV | QuantHealth |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | Not recorded | 2020 |
| Headquarters | Cambridge, Massachusetts, United States | Tel Aviv, Israel |
| Website | phasevtrials.com | quanthealth.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
PhaseV provides clinical development software for pharmaceutical sponsors, biotechnology companies, and contract research organizations. Its analytical modules help teams identify treatment responders, compare trial designs, select sites, and assess development opportunities. Response Optimizer estimates how treatment effects differ across patient groups, while Trial Optimizer simulates fixed, adaptive, and Bayesian designs.
Source: AI Health Index, October 2026
Clinical trial simulation company with offices in Tel Aviv and Worcester, Massachusetts. Its platform predicts how individual patients would respond to an investigational therapy, drawing on a knowledge graph of drug biology and a real world database the company sizes at 350 million lives, and aggregates those predictions into a simulated trial result so sponsors can test protocol, indication and enrollment choices before a study runs.
Source: AI Health Index, October 2026
Questions buyers ask
Which settings and specialties do PhaseV and QuantHealth cover?
For PhaseV, the broader portfolio also targets oncology, immunology, neurological disease, metabolic disease, and rare disease research.
With QuantHealth, the evidence page claims coverage across therapeutic areas, clinical phases and treatment modalities, and case studies span oncology (head and neck, breast, multiple myeloma), inflammatory, metabolic and respiratory disease. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
How much do PhaseV and QuantHealth leave to the clinician?
In PhaseV's case, the boundary between deterministic propagation and model interpretation is not sufficiently specified to resolve that tension. Confidence thresholds, conditions that suspend automated changes, and recovery procedures for missed amendments remain unclear despite the defined human review role.
For QuantHealth, the results go to clinical development, business development and portfolio teams as virtual trial readouts, enrollment curves and probability of success estimates; nothing is actioned on a patient. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
PhaseV is based in Cambridge, Massachusetts. QuantHealth has offices in Tel Aviv and Worcester, Massachusetts. QuantHealth has no public price. PhaseV's marketplace plans exclude some services and integrations, and additional infrastructure charges may apply.